Roth Capital Has Pessimistic Outlook of BRTX FY2028 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Roth Capital decreased their FY2028 earnings per share estimates for BioRestorative Therapies in a report released on Monday, February 10th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of $5.24 per share for the year, down from their previous estimate of $5.40. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ FY2029 earnings at $6.93 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.22. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.30 million. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%.

BioRestorative Therapies Stock Down 5.7 %

Shares of BRTX opened at $2.30 on Tuesday. BioRestorative Therapies has a 52-week low of $1.03 and a 52-week high of $2.55. The stock has a fifty day simple moving average of $1.81 and a two-hundred day simple moving average of $1.66. The company has a market capitalization of $15.92 million, a PE ratio of -1.50 and a beta of 62.62.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.